1. Scrip
  2. >>Conferences
  3. >>J.P. Morgan

Servier Plots Route Into Neurology Through BD

 
• By Jessica Merrill

CEO David Lee, who oversees Servier’s US business, and chief scientific officer Claude Bertrand talked to Scrip at J.P. Morgan about expanding into neurology through business development.

(Shutterstock)
Key Takeaways
  • Servier is looking to speed up development of a neuroscience franchise through business development.
  • Servier Pharmaceuticals CEO David Lee and chief scientific officer Claude Bertrand talked to Scrip at J.P. Morgan about the initiative.
  • The company is hoping to replicate the success it has seen in oncology with the 2020 acquisition of Agios.

Servier Pharmaceuticals CEO David Lee, who oversees the French company’s US business, and chief scientific officer Claude Bertrand were at the J.P

“The reason why we’re here at J.P. Morgan,” Lee said in an interview on the sidelines of the meeting, “[is that] a lot of focus will be inorganic” for the coming year. “We’re definitely very open to deals, both on the M&A side [and] licensure

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from J.P. Morgan

BMS Enters A Catalyst-Rich Era Full Of Both LOEs And New Launches

 
• By Mandy Jackson

Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.

Lilly CMO David Hyman On The Company’s Drive To Take ‘Ambitious Swings’ In R&D

 
• By Mandy Jackson

Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.

Momentum In Women’s Health, But Big Obstacles Too

 
• By Jessica Merrill

Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.

Amgen Building On Repatha Experience As It Grows In Cardiovascular, Obesity

 
• By Mandy Jackson

Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.

More from Neurological